Development and validation of an HPLC–MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue‐related matrices
Biomedical Chromatography · 2023
DOI: 10.1002/bmc.5720 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2023. Verfasst von Irene A Retmana und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands. Hauptthemen laut MEDLINE: Tandem Mass Spectrometry, Proto-Oncogene Proteins p21(ras), Triazoles, Pyrimidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
We developed and validated an assay utilizing a liquid chromatography–tandem mass spectrometry technique to quantify the KRAS inhibitor adagrasib in mouse plasma and seven tissue‐related matrices. The straightforward protein precipitation technique was selected to extract adagrasib and the internal standard salinomycin from the matrices. Gradient elution of acetonitrile and water modified with 0.5% (v/v) ammonium hydroxide and 0.02% (v/v) acetic acid on a C 18 column at a flow rate of 0.6 ml/min was applied to separate the analytes. Both adagrasib and salinomycin were detected with a triple quadrupole mass spectrometer with positive electrospray ionization in a selected reaction monitoring mode. A linear calibration range of 2–2,000 ng/ml of adagrasib was demonstrated during the validation. In addition, the reported precision values (intra‐ and inter‐day) were between 3.5 and 14.9%, while the accuracy values were 85.5–111.0% for all tested levels in all investigated matrices. Adagrasib in mouse plasma was reported to have good stability at room temperature, while adagrasib in tissue‐related matrices was stable on ice for up to 4 h (matrix dependent). Finally, this method was successfully applied to determine the pharmacokinetic profile and tissue distribution of adagrasib in wild‐type mice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
- Division of Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
- Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
- Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
ORCID-Profile: Irene A Retmana, Rolf W Sparidans
Zitieren
APA
Retmana, I. A., Loos, N. H. C., Schinkel, A. H., Beijnen, J. H., & Sparidans, R. W. (2023). Development and validation of an HPLC–MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue‐related matrices. Biomedical Chromatography. https://doi.org/10.1002/bmc.5720
Vancouver
Retmana IA, Loos NHC, Schinkel AH, Beijnen JH, Sparidans RW. Development and validation of an HPLC–MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue‐related matrices. Biomedical Chromatography. 2023. doi:10.1002/bmc.5720
BibTeX
@article{Retmana2023,
author = {Retmana, Irene A and Loos, Nancy H C and Schinkel, Alfred H and Beijnen, Jos H and Sparidans, Rolf W},
title = {Development and validation of an HPLC–MS/MS method to quantify the KRAS inhibitor adagrasib in mouse plasma and tissue‐related matrices},
journal = {Biomedical Chromatography},
year = {2023},
doi = {10.1002/bmc.5720}
}
EUVIMED